The Lyla Nsouli Foundation logo

The Lyla Nsouli Foundation

For Children's Brain Cancer Research in DIPG.

The Lyla Nsouli Foundation for Children's Brain Cancer Research was set up after our beautiful daughter, Lyla, was diagnosed, on August 13, 2011, at the age of 2 years and 8 months with an inoperable, incurable form of brain cancer called Diffuse Intrinsic Pontine Glioma. She was given months to live.

This Foundation was set up to find a cure for Brain Cancer. Its first objective is to target the worst form of brain cancer-DIPG. After what has happened to our daughter we are compelled to do all we can to try and prevent this disease from destroying children's lives (and their families) so violently, and to try and improve the prognosis for these children and eventually find a cure.

Baby Lyla

The Foundation Leadership

Nadim Nsouli

Nadim M Nsouli founded Inspired in 2013 with the goal of creating a leading global group of premium schools.  Starting with Inspired’s first acquisition of Reddam House, a leading group of schools in South Africa, Nadim rapidly expanded the group globally via a series of acquisitions and building greenfield schools while maintaining the focus on only having the best schools around the world as part of the group.

Prior to founding Inspired, Nadim was a partner at Providence Equity Partners, a private equity firm with $40 billion under management. Nadim was also a member of Providence's Global Investment Committee and led Providence's Education investment efforts in Europe and the Middle East.  Prior to joining Providence in 2006, Nadim was the European head of The Gores Group, a special situations private equity fund based in Los Angeles.  Previously, Nadim was a member of the media and telecommunications investment banking teams of Morgan Stanley and J.P. Morgan in London.  Nadim started his career in New York as a corporate lawyer at Jones, Day, Reavis & Pogue.

Nadim received a Master of Business Administration from INSEAD with distinction, a Juris Doctor from New York University School of Law and a Bachelor of Science (magna cum laude) from Georgetown University.
Show more
Show less
Simone Cheetham Nsouli

Simone Cheetham Nsouli completed an MSc from The London School of Economics and Political Science in Media and Communications in 1999 after earning a BA with Distinction from McGill University. She then worked in financial investor relations consulting for several years before beginning a career in fundraising and investor relations in the hedge fund industry.

She worked for Blue Crest Capital and then Man Group Plc as an institutional sales manager for five years before leaving to raise her children.
Show more
Show less
H.R.H. Princess Ghida Talal, Chair, Board of Trustees, King Hussein Cancer Foundation, Jordan

A holder of two honours degrees from Georgetown University’s School of Foreign Service, Princess Ghida married Prince Talal of Jordan in 1991. The late King Hussein appointed her as his Press Secretary and asked her to establish the International Press Office of the Royal Hashemite Court.

In 2001, King Abdullah appointed her as Chairperson of the King Hussein Cancer Foundation. As the wife of a cancer survivor and knowing firsthand the heavy toll that cancer takes on patients and their families, she has devoted herself entirely to the fight against cancer and is a dedicated fundraiser for the King Hussein Cancer Foundation and passionate advocate for cancer patients.

Princess Ghida, born Ghida Salaam in Beirut to a distinguished Lebanese political family, is a board member of the Institute of International Education’s ‘Scholar Rescue Fund’ and has been awarded its Humanitarian Award for International Cooperation. She has also served two terms on Georgetown University’s Board of Regents.
Show more
Show less
Walid Fakhry

Mr Fakhry co-founded Core Capital in 2004, a leading mid-market growth capital focused private equity house with over £100m in assets under management and investments in 13 companies across a range of sectors.

He has over eight years’ private equity investment experience. Before founding Core, he was a Partner at Lago Partners, which focused on growth and early-stage investment in technology-driven businesses in Europe and the US. Previously, Mr Fakhry was a member of the TMT corporate finance group at JP Morgan, before which he acted as an entrepreneur, establishing several technology-related businesses including one of the leading ISPs in the Middle East, Cyberia Sal.

He began his professional career at Gemini Consulting, working mainly on operational restructuring. Mr Fakhry has particular experience of investing in service-led Telecoms and IT businesses. He has a BSc in Mechanical Engineering, a BSc in Finance and an MSc in Civil and Environmental Engineering from the Massachusetts Institute of Technology (MIT).
Show more
Show less

Scientific Advisory Board

Dr. Eric Bouffet

Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto.

Dr. Bouffet is a Professor of Paediatrics in the University of Toronto, Garron Family Chair in Childhood Cancer Research and Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto.

He graduated in 1980 from the medical school at the University of Lyon. Following graduation he trained and practiced in Lyon; he was Head of the Department of Neuro-oncology, Centre Leon Berard, during the period 1992-1995. Dr. Bouffet then moved to the United Kingdom where he was Consultant Paediatric Oncologist at the Hospital for Sick Children, Bristol (1996-1998) and the Royal Marsden Hospital, Sutton UK (1998-2000). In 2000 he was recruited to The Hospital for Sick Children in Toronto to develop and Head a multidisciplinary paediatric Neuro-oncology Program within the Division of Haematology/Oncology.

In 1998-2001 he was co-Chairman of the Brain Tumour Committee of the International Society of Pediatric Oncology (SIOP) and is currently Chair of the Canadian Paediatric Brain Tumour Consortium. Dr. Bouffet is a member of the steering committee of the brain tumour committee of the Children's Oncology Group, and chair of the Infant Brain Tumours Committee. He is a Senior Associate Scientist in the Research Institute at the Hospital for Sick Children.

Dr. Bouffet's research interests are in the area of novel treatments and clinical trials in children with brain tumours. He is the author or co-author of over 260 peer-reviewed manuscripts and author/co-author on numerous book chapters in the field of neuro-oncology. He was the recipient of several awards, including the Alvin Zipursky Teaching Award, the Claus Wirsig Humanitarian Award, the Richard Rowe Award for Clinical Excellence in Paediatric Medical Care. In 2011, he became the inaugural recipient of the Garron Family Chair in Childhood Cancer Research.
Show more
Show less
Dr. Maryam Fouladi

Medical Director, Neuro-Oncology Program. Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network.

Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology/oncology fellowship training at the Hospital for Sick Children in Toronto, Canada.

Dr. Fouladi then completed her neuro-oncology fellowship training at St Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St Jude before becoming a neuro-oncology faculty member in 2000. She served as the Chair of the Phase I Committee at St Jude.Dr.

Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children's Oncology Group. She is a member of the Steering Committee for the COG CNS Tumor Committee as well as the Developmental Theerapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN).

She serves as local and national study chair through CERN, COG and the Pediatric Brain Tumor Consortium, for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Show more
Show less
Dr. Darren Hargrave

Consultant Paediatric Oncologist at Great Ormond Street Hospital in London.

Dr. Hargrave is a Consultant Paediatric Oncologist at Great Ormond Street Hospital (GOSH) for Children in London, UK. His clinical speciality is neuro-onology and he leads the Experimental Cancer Therapeutics programme at GOSH.

Dr. Hargrave trained in the UK and Canada and has worked at the Hospital for Sick Children in Toronto, the Royal Marsden Hospital and now at GOSH. His particular interest is malignant glioma, including brainstem tumours (Diffuse Intrinsic Pontine Glioma- DIPG) and he has led several completed, on-going and planned clinical trials in these poor prognosis brain tumours.

He currently Chairs the European Paediatric High Grade Glioma group. Dr. Hargrave is also involved with collaborative research investigating the molecular biology and advanced functional imaging of malignant glioma and DIPG. The Experimental Cancer Therapeutics programme aims to develop new therapies against high risk childhood cancer and includes targeted and immune directed therapy strategies working with academics and Pharmaceutical partners.

One of his career aims is to help deliver an improvement in the survival and quality of life with children with high risk brain tumours such as DIPG.
Show more
Show less
Prof. Charles Keller

Associate Professor and Leader of the Pediatric Cancer Biology Program in the Pape' Family Pediatric Research Institute, Department of Pediatrics, Oregon Health & Science University.

Dr. Keller's research focuses on the development of more effective, less toxic therapies for the childhood brain tumor, medulloblastoma, and the childhood muscle cancer, rhabdomyosarcoma. His special interest is advanced disease that has spread beyond the initial location of the cancer.

Dr. Keller is an Associate Professor and Leader of the Pediatric Cancer Biology Program in the Pape' Family Pediatric Research Institute, Department of Pediatrics, Oregon Health & Science University. Dr. Keller also directs the Pediatric Preclinical Testing Initiative, an NCI-affiliated childhood cancer drug testing program. He co-chairs the brain tumor developmental therapeutics committee (CNS-DVL) of the Children's Oncology Group and is a member of the soft tissue sarcoma (STS) committee of COG.

Dr. Keller previously attended Tulane University where he received a degree in Biomedical Engineering prior to attending Baylor College of Medicine where he received his M.D. degree. After completing his internship and residency in Pediatrics at Texas Children's Hospital, Dr. Keller trained in Pediatric Hematology-Oncology at the University of Utah and with 2007 Nobel laureate, Mario Capecchi.

More information on Prof. Charles Keller blog.
Show more
Show less
Dr. Clinton Stewart

Full Member in the Department of Parmaceutical Sciences at St. Jude Children's Research Hospital.

Dr. Clinton Stewart is a Full Member in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital and Professor of Pediatrics and Clinical Pharmacy at the University of Tennessee, Memphis. He received his B.S. degree in Pharmacy from Auburn University and his Doctor of Pharmacy from the University of Tennessee, Memphis. After completing a postdoctoral fellowship at St. Jude under the mentorship of Dr. William E. Evans, Dr. Stewart joined the University of Tennessee College of Pharmacy faculty; in 1991, he joined the St. Jude faculty.

Dr. Stewart is an active member of several professional organizations, including the American Association of Pharmaceutical Scientists, the American Society of Clinical Oncology, and the American Association of Cancer Research. His research efforts are focused in the area of pediatric clinical pharmacology, addressing clinically relevant problems of cancer therapeutics in children. Current research efforts include the use of preclinical models to enhance design of clinical trials of new agents in children with cancer and the use of pharmacokinetics as a method to optimize drug exposure in children with cancer.

Dr. Stewart has authored or co-authored more than 200 peer-reviewed articles and book chapters. Co-chair of the Pharmacology Committee of the NIH-funded Pediatric Brain Tumor Consortium, Dr. Stewart has an active research program focused on developing a better understanding of the CNS penetration of anticancer drugs.
Show more
Show less

The Fundraising Committee

The following individuals have kindly agreed to join the Fundraising Committee to assist in raising awareness and funds on behalf of the Foundation:

Iman Dakhil
Veronica De Piante
Dima Fakhry
Dexter Goei
Raja Hadji-Touma
Mira Mikati
Roxana Sursock

What can you do to help?

There's a lot of things we need you for.

Donate today

Your online donation will go directly towards our fight for a DIPG cure.

Take action

Discover how you can help support us through activities like fundraising.

Follow us

Never miss an announcement - stay connected with us through social media.

Financial statements